Skip to main content
Journal cover image

Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.

Publication ,  Journal Article
Naggie, S; Hicks, C
Published in: J Antimicrob Chemother
June 2010

The introduction of protease inhibitors (PIs) to HIV treatment combinations in 1996 has significantly reduced morbidity and mortality due to HIV infection. Since the 1990s, multiple PIs have been approved, with several boosted PI regimens recognized as first-line regimens in antiretroviral therapy (ART)-naive patients. While the current guidelines recommend non-nucleoside reverse transcriptase inhibitor-, PI- and integrase inhibitor-based regimens as equal alternatives in ART-naive patients, there are clearly selected patients for whom PI-based regimens appear to be the best option because of specific toxicity or dosing issues. Due to the multiple options of therapy available for ART-naive patients, providers initiating PI-based ART can individualize therapy based on patient characteristics and needs, including pre-treatment resistance, drug-drug interactions, adverse effect profiles and co-morbid conditions. Here, we discuss the current recommendations and recent guidelines, and the evidence available for various PI-based ART regimens in treatment-naive patients. We also discuss adverse effects and the use of PIs in special circumstances.

Duke Scholars

Published In

J Antimicrob Chemother

DOI

EISSN

1460-2091

Publication Date

June 2010

Volume

65

Issue

6

Start / End Page

1094 / 1099

Location

England

Related Subject Headings

  • Practice Guidelines as Topic
  • Microbiology
  • Humans
  • HIV-1
  • HIV Protease Inhibitors
  • HIV Infections
  • Antiretroviral Therapy, Highly Active
  • 3214 Pharmacology and pharmaceutical sciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Naggie, S., & Hicks, C. (2010). Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother, 65(6), 1094–1099. https://doi.org/10.1093/jac/dkq130
Naggie, Susanna, and Charles Hicks. “Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.J Antimicrob Chemother 65, no. 6 (June 2010): 1094–99. https://doi.org/10.1093/jac/dkq130.
Naggie, Susanna, and Charles Hicks. “Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.J Antimicrob Chemother, vol. 65, no. 6, June 2010, pp. 1094–99. Pubmed, doi:10.1093/jac/dkq130.
Journal cover image

Published In

J Antimicrob Chemother

DOI

EISSN

1460-2091

Publication Date

June 2010

Volume

65

Issue

6

Start / End Page

1094 / 1099

Location

England

Related Subject Headings

  • Practice Guidelines as Topic
  • Microbiology
  • Humans
  • HIV-1
  • HIV Protease Inhibitors
  • HIV Infections
  • Antiretroviral Therapy, Highly Active
  • 3214 Pharmacology and pharmaceutical sciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences